Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
2(33%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_3
2
33%
Ph early_phase_1
1
17%
Ph phase_2
3
50%

Phase Distribution

1

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(4)

Detailed Status

Completed4
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (16.7%)
Phase 23 (50.0%)
Phase 32 (33.3%)

Trials by Status

active_not_recruiting117%
recruiting117%
completed467%

Recent Activity

2 active trials
Showing 5 of 6
recruitingearly_phase_1

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

NCT04161248
active_not_recruitingphase_2

Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

NCT01808599
completedphase_2

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

NCT04660799
completedphase_3

Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)

NCT02303119
completedphase_2

Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy

NCT02042391
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04161248Early Phase 1

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Recruiting
NCT01808599Phase 2

Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

Active Not Recruiting
NCT04660799Phase 2

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Completed
NCT02303119Phase 3

Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)

Completed
NCT02042391Phase 2

Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy

Completed
NCT01200758Phase 3

A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6